Legend Biotech, a biopharmaceutical company focused on cell therapies, said it achieved adjusted net income profitability in the second quarter, powered by rapid sales growth of its multiple myeloma treatment Carvykti. The milestone marks a shift from heavy investment toward sustainable earnings, a key transition for a company that has long been in growth mode.
According to RBC Capital Markets, Legend's Q2 revenue reached $387.5 million, up from $255.1 million in the same period last year. The bulk of that growth came from Carvykti, a CAR-T cell therapy that Legend developed in partnership with Johnson & Johnson, the global healthcare giant. CAR-T therapies work by reprogramming a patient's own immune cells to attack cancer, and Carvykti targets a protein called BCMA that is commonly found on myeloma cells.
Why Carvykti is gaining traction
RBC notes that Carvykti is still gaining market share as it moves into earlier lines of treatment. The therapy is currently approved for patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, but the company is pushing to expand its use to earlier stages of the disease. That expansion is opening up a larger patient pool and driving revenue growth.
The bank also highlights that demand in the second- to fourth-line myeloma setting remains relatively under-served by BCMA-targeting drugs. BCMA is a protein that is highly expressed on myeloma cells, making it a prime target for therapies like Carvykti. While other BCMA-directed treatments exist, including antibody-drug conjugates and bispecific antibodies, the market is still growing, and Carvykti appears to be capturing a significant share.
This is not just a story about one drug. Legend's ability to turn growth into profit is a signal that the company is maturing. For years, biotech firms often prioritize revenue expansion over profitability, burning through cash to fund research and development. Legend's move to adjusted net income profitability suggests that its commercial infrastructure is becoming more efficient, and that the cost of manufacturing and selling Carvykti is being offset by higher sales.
Cash runway supports momentum
RBC believes Legend has enough cash on hand to sustain this profitability trend. A strong cash position is crucial for a biotech company, as it provides a buffer against unexpected expenses and allows for continued investment in pipeline development without the need to raise additional capital through dilutive stock offerings.
For investors, the combination of revenue growth and profitability is often seen as a positive sign. It indicates that the company is not only selling its product but doing so in a way that generates real earnings. This can make the stock more attractive to a broader range of investors, including those who focus on fundamentals rather than just growth potential.
However, it's important to note that adjusted net income profitability may exclude certain one-time costs or stock-based compensation. Investors should look at the full financial statements to understand the quality of the earnings. Still, the trend is encouraging.
What it means for investors
For everyday investors, the key takeaway is that Legend Biotech is transitioning from a high-risk, high-reward biotech play to a more established company with a commercial product that is generating real profits. This could reduce the volatility associated with the stock, though biotech remains a sector with inherent risks, including regulatory changes, competition, and manufacturing challenges.
RBC's positive outlook is based on the belief that Carvykti's growth will continue as it moves into earlier lines of therapy and as the overall market for BCMA-targeting drugs expands. The company's partnership with Johnson & Johnson also provides a strong commercial and manufacturing backbone, which is critical for a complex cell therapy like Carvykti.
Investors should also consider the broader context of the biotech sector. Many companies in this space are still in the red, so Legend's profitability is a differentiator. But it's not the only company making strides. For instance, Titan Mining swung to profit on higher zinc output, showing that profitability can come from various sectors. Similarly, Kontoor raised its profit outlook after a solid quarter, another example of companies improving earnings.
Looking ahead, investors will likely watch for updates on Carvykti's label expansion, as well as any data on its use in earlier lines of therapy. They'll also monitor Legend's cash burn and whether it can maintain profitability while investing in its pipeline. The company's ability to balance growth and profitability will be key to its long-term success.
In summary, Legend Biotech's Q2 results are a positive sign for the company and its shareholders. The revenue jump and move to profitability, supported by a solid cash runway, suggest that Carvykti is not just a promising therapy but a commercially viable one. As with any investment, it's important to do your own research and consider your risk tolerance, but this is a development worth noting for anyone following the biotech space.
